Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-09-13
2005-09-13
Lukton, David (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S385000, C514S386000, C514S387000, C514S393000, C514S394000, C548S300100, C548S305700, C546S273400
Reexamination Certificate
active
06943149
ABSTRACT:
The invention is directed to novel benzimidazolone peptidomimetic compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, Angiogenesis related disorders, cancer, and neurodegenerative disorders. Pharmaceutical compositions comprising the substituted benzimidazolone peptidomimetics of the present invention and methods of treating conditions mediated by the thrombin receptor are also disclosed.
REFERENCES:
patent: 4977153 (1990-12-01), Louis et al.
patent: 5439906 (1995-08-01), Bock et al.
patent: 5530026 (1996-06-01), Gaudreault et al.
patent: 6017890 (2000-01-01), Hoekstra et al.
patent: 6365617 (2002-04-01), McComsey et al.
patent: 2011222 (1990-04-01), None
patent: 0 385 850 (1990-09-01), None
patent: WO 92/14750 (1992-09-01), None
patent: WO 92/14760 (1992-09-01), None
patent: WO 93/18026 (1993-09-01), None
patent: WO 99/00357 (1999-01-01), None
patent: WO 99/33798 (1999-07-01), None
patent: WO 99/42475 (1999-08-01), None
“Cloning and Characterization of Human Protease-Activated Receptor 4”, Wen-Feng Xu et al., Proc. Natl. Acad. Sci. USA, vol. 95, Jun. 1998, pp. 6642-6646.
“Molecular Cloning of a Potential Proteinase Activated Receptor”, Sverker Nystedt et al., Proc. Natl. Acad. Sci. USA, vol. 91, Sep. 1994, pp. 9208-9212.
“Thrombin-Induced Events in Non-Platelet Cells are Mediated by the Unique Proteolytic Mechanism Established for the Cloned Platelet Thrombin Receptor”, David T. Hung. et al., The Journal of Cell Biology, vol. 116, No. 3, Feb. 1992, pp. 827-832.
Thrombin Receptor Activation Causes Rapid Neural Cell Rounding and Neurite Retraction Independent of Classic Second Messengers, Kees Jalink et al., The Journal of Cell Biology, vol. 118, No. 2, Jul. 1992, pp. 411-419.
“Thrombin-Induced Expression of Endothelial P-Selectin and Intercellular Adhesion Molecule-1: A Mechanism for Stabilizing Neutrophil Adhesion”, Yasuo Sugama et al., The Journal of Cell Biology, vol. 119, No. 4, Nov. 1992, pp. 935-944.
“Molecular Cloning of a Functional Thrombin Receptor Reveals a Novel Proteolytic Mechanism of Receptor Activation”, Thien-Khal H. Vu et al., Cell, vol. 64, Mar. 1991, pp. 1057-1068.
“Response of a Human Megakaryocytic Cell Line to Thrombin: Increase in Intracellular Free Calcium and Mitogen Release”, Cindy L. A. Jones, et al., Biochemica et Bioophysica Acta. 1136, 1992, pp. 272-282.
“Thrombin Effects on Osteoblastic Cells—II. Structure-Function Relatoinships” Dimitris N. Tatakis et al., Biochemical and Biophysical Research Communications, vol. 174, No. 1, Jan. 1991, pp. 181-188.
“Condensed Heteroaromatic Ring Systems—XIII. One-Step Synthesis of 2-Substituted 1-Methylsulfoonylindoles From N-(2-Halophenyl) Methanesulfonamides”, Takao Sakamoto et al., Chem. Pharm. Bull., No. 4, Sep. 1987, pp. 1305-1308.
“An Antibody Against the Exosite of the Cloned Thrombin Receptor Inhibits Experimental Arterial Thrombosis in the African Green Monkey”, Jacquelynn J. Cook et al., Basic Science Reports, Oct. 1994, pp. 2961-2971.
“Protease-Activated Receptor 3 is a Second Thrombin Receptor in Humans”, Hiroaki Ishihara, Nature, vol. 386, Apr. 1997, pp. 502-508.
“Heterocycle-Peptide Hybrid Compounds, Aminotriazole-Containing Agonists of the Thrombin Receptor (PAR-1)”, David F. McComsey et al., Bioorganic & Medicinal Chemistry Letters 9 (1999), pp. 1423-1428.
“Design, Synthesis, and Biological Characterization of a Peptide-Mimetic Antagonist for a Tethered-Ligand Receptor”, Patricia Andrade-Gordon et al., PNAS, vol. 96, No. 22, Oct. 28, 1999, pp. 12257-12262.
Thrombin Receptor (PAR-1) Antagoonists, Heterocycle-Based Peptidomimetics of the SFLLR Agonist Motif, William J. Hoekstra et al., Bioorganic & Medicinal Chemistry Letters 8, (1998), pp. 1649-1654.
“Development of Potent Thrombin Receptor Antagonist Peptides”, Michael S. Bernatowicz et al., J. Med. Chem., 1996, vol. 39, No. 25, pp. 4879-4887.
“Approaches to the Synthesis of Ureapeptoid Peptidomimetics”, John A. W. Kruijtzer et al., Tetraehedron Letters, vol. 36, No. 30, pp. 5335-5338, 1997.
PCT Search Report for corresponding PCT application (PCT/US 00/17751) dated Nov. 10, 2000.
PCT Search Report for corresponding divisional PCT application (PCT/US 00/17718) dated Feb. 5, 2001.
Maryanoff Bruce E.
McComsey David F.
White Kimberly B.
Zhang Han-Cheng
Lopez Gabriel
Lukton David
Millennium Pharmaceuticals Inc.
Ortho -McNeil Pharmaceutical, Inc.
Woodrow Hal
LandOfFree
Benzimidazolone peptidomimetics as thrombin receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzimidazolone peptidomimetics as thrombin receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzimidazolone peptidomimetics as thrombin receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3383883